Patent intelligence · US
US 11229600
Compositions and methods for selective GI tract delivery
Compositions and methods for selective GI tract delivery
Patent details — US 11229600
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 25, 2022
- Expiration
- Jan 20, 2042
- Applicant
- VITAL BEVERAGES GLOBAL INC.
- Claims
- 16
- CPC classes
- A61K, A61K31/05, A61K31/12, A61K31/198
Quick answer
US 11229600 (Compositions and methods for selective GI tract delivery) is held by VITAL BEVERAGES GLOBAL INC.. Status: granted. Granted Jan 25, 2022. Expires Jan 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- VITAL BEVERAGES GLOBAL INC.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/05, A61K31/12, A61K31/198, A61K31/352, A61K31/355
More from VITAL BEVERAGES GLOBAL INC.
Related pharmaceutical patents in our USPTO index.
-
US 12403164
Lentiviral vector formulations
granted -
US 12403183
Factor VIII polypeptide formulations
granted -
US 12391750
Anti-C1S antibodies and methods of use thereof
granted -
US 12371747
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
granted -
US 12364774
Nucleic acid molecules and uses thereof for non-viral gene therapy
granted -
US 12268688
Compositions and methods of use for modified release minoxidil
granted -
US 12257288
Methods of inducing immune tolerance to clotting factors
granted -
US 12240917
Anti-complement C1s antibodies and uses thereof
granted
Frequently asked questions
What is US patent 11229600?
US 11229600 (Compositions and methods for selective GI tract delivery) is held by VITAL BEVERAGES GLOBAL INC.. Status: granted. Granted Jan 25, 2022. Expires Jan 20, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11229600?
VITAL BEVERAGES GLOBAL INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 140 pharmaceutical patents for this assignee.
When does US 11229600 expire?
Our index shows an expiration date of Jan 20, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.